TY - JOUR
T1 - Rare Genome-Wide Copy Number Variation and Expression of Schizophrenia in 22q11.2 Deletion Syndrome
AU - Bassett, Anne S.
AU - Lowther, Chelsea
AU - Merico, Daniele
AU - Costain, Gregory
AU - Chow, Eva W C
AU - Van Amelsvoort, Therese
AU - McDonald-Mcginn, Donna M.
AU - Gur, Raquel E.
AU - Swillen, Ann
AU - van den Bree, Marianne B M
AU - Murphy, Kieran C.
AU - Gothelf, Doron
AU - Bearden, Carrie E.
AU - Eliez, Stephan
AU - Kates, Wendy R.
AU - Philip, Nicole
AU - Sashi, Vandana
AU - Campbell, Linda E.
AU - Vorstman, Jacob
AU - Cubells, Joseph
AU - Repetto, Gabriela M.
AU - Simon, Tony J.
AU - Boot, Erik
AU - Heung, Tracy
AU - Evers, Rens
AU - Vingerhoets, Claudia
AU - Van Duin, Esther
AU - Zackai, Elaine
AU - Vergaelen, Elfi
AU - Devriendt, Koen
AU - Vermeesch, Joris R.
AU - Owen, Michael J
AU - Murphy, Clodagh M.
AU - Michaelovosky, Elena
AU - Kushan, Leila
AU - Schneider, Maude
AU - Fremont, Wanda
AU - Busa, Tiffany
AU - Hooper, Stephen R.
AU - McCabe, Kathryn
AU - Duijff, Sasja
AU - Isaev, Karin
AU - Pellecchia, Giovanna
AU - Wei, John
AU - Gazzellone, Matthew J.
AU - Scherer, Stephen W.
AU - Emanuel, Beverly S.
AU - Guo, Tingwei
AU - Morrow, Bernice E.
AU - Marshall, Christian R.
N1 - Funding Information:
Supported by NIMH grant 5U01MH101723-02, by the Canadian Institutes of Health Research (MOP numbers 97800 and 111238 to Dr. Bassett), by the Canada Research Chair in Schizophrenia Genetics and Genomic Disorders (Dr. Bassett), by Canada-Latin America and the Caribbean Research Exchange Grants program (Dr. Bassett and Dr. Repetto), and by the University of Toronto McLaughlin Centre (MC-2015-01). Dr. Bassett also is supported by the Dalglish Chair at the University Health Network, Toronto. Ms. Lowther is supported by a Frederick Banting and Charles Best Canadian Institutes of Health Research Doctoral Award. Dr. Vorstman was funded for this work by a Young Investigator Award from the Brain and Behavior Research Foundation. The authors thank all of the subjects with 22q11.2 deletion syndrome and their families for their generous contributions to this and related research studies. The authors express gratitude to the students, research assistants, and staff affiliated with the Clinical Genetics Research Program and the Centre for Applied Genomics. The authors also thank Gladys Wong for her help with formatting and referencing. The authors report no financial relationships with commercial interests.
Publisher Copyright:
© 2017 American Psychiatric Association.
PY - 2017/11/1
Y1 - 2017/11/1
N2 - Objective: Chromosome 22q11.2 deletion syndrome (22q11.2DS) is associated with a more than 20-fold increased risk for developing schizophrenia. The aim of this studywas to identify additional genetic factors (i.e., "second hits") that may contribute to schizophrenia expression. Method: Through an international consortium, the authors obtained DNA samples from 329 psychiatrically phenotyped subjects with 22q11.2DS. Using a high-resolution microarray platform and established methods to assess copy number variation (CNV), the authors compared the genome-wide burden of rare autosomal CNV, outside of the 22q11.2 deletion region, between two groups: A schizophrenia group and those with no psychotic disorder at age≥25 years. The authors assessedwhether genes overlapped by rare CNVs were overrepresented in functional pathways relevant to schizophrenia. Results: Rare CNVs overlapping one or more protein-coding genes revealed significant between-group differences. For rare exonic duplications, six of 19 gene sets tested were enriched in the schizophrenia group; genes associated with abnormal nervous system phenotypes remained significant in a stepwise logistic regression model and showed significant interactions with 22q11.2 deletion region genes in a connectivity analysis. For rare exonic deletions, the schizophrenia group had, on average, more genes overlapped. The additional rare CNVs implicated known (e.g., GRM7, 15q13.3, 16p12.2) and novel schizophrenia risk genes and loci. Conclusions: The results suggest that additional rare CNVs overlapping genes outside of the 22q11.2 deletion region contribute to schizophrenia risk in 22q11.2DS, supporting a multigenic hypothesis for schizophrenia. The findings have implications for understanding expression of psychotic illness and herald the importance of whole-genome sequencing to appreciate the overall genomic architecture of schizophrenia.
AB - Objective: Chromosome 22q11.2 deletion syndrome (22q11.2DS) is associated with a more than 20-fold increased risk for developing schizophrenia. The aim of this studywas to identify additional genetic factors (i.e., "second hits") that may contribute to schizophrenia expression. Method: Through an international consortium, the authors obtained DNA samples from 329 psychiatrically phenotyped subjects with 22q11.2DS. Using a high-resolution microarray platform and established methods to assess copy number variation (CNV), the authors compared the genome-wide burden of rare autosomal CNV, outside of the 22q11.2 deletion region, between two groups: A schizophrenia group and those with no psychotic disorder at age≥25 years. The authors assessedwhether genes overlapped by rare CNVs were overrepresented in functional pathways relevant to schizophrenia. Results: Rare CNVs overlapping one or more protein-coding genes revealed significant between-group differences. For rare exonic duplications, six of 19 gene sets tested were enriched in the schizophrenia group; genes associated with abnormal nervous system phenotypes remained significant in a stepwise logistic regression model and showed significant interactions with 22q11.2 deletion region genes in a connectivity analysis. For rare exonic deletions, the schizophrenia group had, on average, more genes overlapped. The additional rare CNVs implicated known (e.g., GRM7, 15q13.3, 16p12.2) and novel schizophrenia risk genes and loci. Conclusions: The results suggest that additional rare CNVs overlapping genes outside of the 22q11.2 deletion region contribute to schizophrenia risk in 22q11.2DS, supporting a multigenic hypothesis for schizophrenia. The findings have implications for understanding expression of psychotic illness and herald the importance of whole-genome sequencing to appreciate the overall genomic architecture of schizophrenia.
UR - http://www.scopus.com/inward/record.url?scp=85032969720&partnerID=8YFLogxK
U2 - 10.1176/appi.ajp.2017.16121417
DO - 10.1176/appi.ajp.2017.16121417
M3 - Article
C2 - 28750581
AN - SCOPUS:85032969720
SN - 0002-953X
VL - 174
SP - 1054
EP - 1063
JO - American Journal of Psychiatry
JF - American Journal of Psychiatry
IS - 11
ER -